Showing results (631-640 of 673) with videos related to

Sort By:
Pageof 68
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
American Journal of Hematology|September 6, 2023
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemiaMyrthe J van Dijk, Brigitte A van Oirschot, Alexander N Harrison, et al.
Obesity (Silver Spring, Md.)|October 15, 2013
Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dogMarilyn Ader, Darko Stefanovski, Stella P Kim, et al.
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Translational Psychiatry|July 15, 2015
Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onsetM K Chan, M-O Krebs, D Cox, et al.
Blood|February 21, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsHolly L Geyer, Robyn M Scherber, Amylou C Dueck, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Nature Cancer|August 7, 2023
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasmsElodie Grockowiak, Claudia Korn, Justyna Rak, et al.
BMC Medical Education|July 2, 2025
Achievement emotions in healthcare education: understanding the application of achievement emotions questionnaireFraide A Ganotice, Xiaoai Shen, John Ian Wilzon Tolentino Dizon, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Pageof 68